AstraZeneca nets lightning-fast lymphoma nod for Imbruvica rival Calquence
admin 31st October 2017 Uncategorised 0AbbVie and Johnson & Johnson got a scare this Halloween, and it came in the form of an FDA approval for AstraZeneca’s Imbruvica rival. AZ certainly hopes the medication pays off: It was the centerpiece of a $4 billion-plus deal with developer Acerta.
More: AstraZeneca nets lightning-fast lymphoma nod for Imbruvica rival Calquence
Source: fierce